ABSTRACT
Radiation pneumonitis (RP) is the most common adverse event of thoracic radiotherapy, which primarily occurs within the 3 months after the beginning of radiotherapy. RP can not only negatively affect the pulmonary function and quality of life of patients, but also limit the prescribed dose and the implementation of radiotherapy plan, lower the radiotherapy efficacy and even lead to death. Currently, multiple studies have been conducted to explore the predictive factors of RP. In this article, clinical predictive factors including dosimetric parameters, peripheral blood cells along with cytokines and pulmonary function parameters were classified and illustrated, aiming to provide valuable predictive indicators for clinical use and reduce the incidence of RP.
ABSTRACT
Objective To analyze the correlation between ≥grade 2 radiation pneumonitis (RP) and dose volume parameters of elderly patients with esophageal cancer after three-dimensional conformal radiotherapy. Methods We collected the data of 250 elderly patients with esophageal cancer who received three-dimensional conformal radiotherapy from different medical centers. The clinical features of patients were analyzed by Chi-square test while dose volume parameters were analyzed by Logistic univariate and multivariate analyses. ROC curve was used to determine the best cut-off value. Results After three-dimensional conformal radiotherapy, 20% of patients developed ≥grade 2 RP. Univariate analysis showed that bilateral pulmonary V5, V10, V20, V30 and mean lung dose were associated with ≥grade 2 RP but multivariate analysis revealed that only V5 and V20 were independent relevant factors of RP. ROC curve indicated that the best cut-off value was V5 < 52.9% and V20 < 23.2%. Conclusion Bilateral pulmonary V5 and V20 are independently related to ≥grade 2 RP in elderly patients with esophageal cancer after 3-D conformal radiotherapy.
ABSTRACT
Objective To observe the efifcacy and safety of ticagrelor in patients received percutaneous coronary intervention (PCI). Methods 50 patients with non-responding platelet aggregation rate and CYPC219 gene after clopidogrel treatment were given ticagrelor and enrolled in the study. All enrolled patients received aspirin loading dosage 300 mg, followed by maintenance dosage 100 mg, once daily and ticagrelor maintenance dosage 90 mg twice daily, for 1 year. The primary endpoint for the study were the incidence of major cardiovascular events (including death, stent thrombosis, stent restenosis, nonfatal myocardial infarction, target vessel revascularization) and stroke after followed up for a month. The secondary endpoint were the incidence of general events (including minor bleeding, allergies, breathing dififculties) and platelet count changes. Results No occur major cardiovascular and stroke events record after 1 month of ticagrelor treatment. The general events rates included 2 cases of dyspnen, 1 case of epitaxis and 1 case of subcutaneous bleeding. The platelet aggregation with ticagrelor was signiifcantly lower than clopidogrel without signiifcant decrease in platelets count. Conclusions Using ticagrelor for antiplatelet in patients with coronary artery stenting in clopidogrel resistance cases is safe and effective.
ABSTRACT
Purpose: To observe the efficacy of intraperitoneal chemotherapy on advanced gastric cancer after radical treatment. Methods: 64 cases of patients with stage Ⅱ - Ⅲ treated by radical surgery were selected and randomly divided into systematic plus intraperitoneal chemotherapy group and systemic chemotherapy group. 3-year survival rate and 3-year recurrence rate were recorded. Results: The recurrence rate for the intraperitoneal chemotherapy group was 18.75% while the control was 43. 33% (P